Precede Biosciences Unveils Liquid Biopsy Platform for Small Cell Lung Cancer Target Expression at ESMO 2025
核心洞察
Precede Biosciences (搜索) presented new data at ESMO 2025 demonstrating its liquid biopsy platform's ability to resolve drug target expression in small cell lung cancer using just 1 mL of patient plasma.
The platform combines comprehensive epigenomic profiling of circulating tumor DNA with machine learning to identify clinically relevant targets including DLL3 (搜索), SEZ6 (搜索), and CEACAM5 (搜索).
The technology can classify SCLC molecular subtypes including ASCL1 (搜索), NEUROD1 (搜索), POU2F3 (搜索), and triple negative, potentially informing therapeutic decision-making in this challenging disease.
Precede Biosciences (搜索) announced new data at the European Society for Medical Oncology (ESMO) Congress 2025 demonstrating its liquid biopsy platform's capability to resolve drug target expression and molecular subtypes in small cell lung cancer (SCLC) from a simple blood draw. The presentation, held October 17-21, 2025, in Berlin, Germany, showcases the potential for non-invasive precision medicine approaches in one of oncology's most challenging diseases.
Platform Technology and Capabilities
Precede Bio's platform combines comprehensive epigenomic profiling of circulating tumor DNA (ctDNA) with machine learning algorithms to resolve gene expression for thousands of cancer genes from just 1 mL of patient plasma. The technology goes beyond conventional profiling by integrating comprehensive epigenomic data with advanced computational approaches to infer gene expression, including key drug targets and master transcription factors.
The ESMO 2025 data highlight the platform's ability to resolve the expression of clinically relevant drug targets such as DLL3 (搜索), SEZ6 (搜索), and CEACAM5 (搜索). Additionally, the platform can classify SCLC molecular subtypes including ASCL1 (搜索), NEUROD1 (搜索), POU2F3 (搜索), and triple negative classifications.
Clinical Context and Unmet Need
Small cell lung cancer accounts for 15% of all lung cancers and remains an aggressive disease with median survival of approximately 12 months for patients with extensive-stage disease. The disease presents significant therapeutic challenges with limited tools available to guide therapy selection for emerging treatment modalities.
"SCLC remains one of the most difficult cancers to treat, with limited tools to guide therapy selection for emerging modalities such as targeted small molecules, antibody drug conjugates, immune conjugates, and radioligand therapies," said J. Carl Barrett, PhD, Chief Scientific Officer at Precede Biosciences (搜索).
Therapeutic Decision-Making Implications
The findings illustrate the potential of Precede Bio's platform to inform biology-based therapeutic decision-making in SCLC, particularly as the field sees many promising emerging therapies. Barrett emphasized that the approach may provide a powerful, non-invasive means to inform therapeutic decision-making and longitudinal disease monitoring in SCLC.
"By uncovering the expression of targets such as DLL3 (搜索), SEZ6 (搜索), and CEACAM5 (搜索), and by resolving molecular subtypes including ASCL1 (搜索), NEUROD1 (搜索), POU2F3 (搜索), and triple negative, our approach may provide a powerful, non-invasive means to inform therapeutic decision-making and longitudinal disease monitoring in SCLC," Barrett stated.
Company Mission and Platform Availability
Precede Biosciences (搜索) positions itself as breaking down barriers to precision medicine by redefining what can be learned from a simple blood draw. The company seeks to improve success rates in drug development and build a future where every patient can receive rapid, minimally invasive diagnosis and therapy precise to their disease biology.
The platform is currently available to drug developers and academic researchers, supporting both drug development efforts and clinical practice applications. By understanding the fundamental biology behind disease at any given moment, the technology aims to help researchers and clinicians better target medicines to the right patients.